An Immunohistochemical Study on the Expression of SUMO-2/3 in the Colorectal Carcinoma.
- Author:
Joo Hyun HAM
1
;
Jung PARK
;
Doo San PARK
;
Sung Su LEE
;
Seung Ha YANG
;
Dongjun JEONG
Author Information
1. Department of Health Management, Hanseo University, Seosan, Korea.
- Publication Type:Original Article
- Keywords:
Colorectal neoplasms;
Small ubiquitin-related modifier;
Immunohistochemistry;
Tissue array analysis
- MeSH:
Acetylation;
Actins;
Blotting, Western;
Cell Line;
Colon;
Colorectal Neoplasms;
Genes, Tumor Suppressor;
Immunohistochemistry;
Incidence;
Korea;
Life Style;
Methylation;
Oncogenes;
Phosphorylation;
Protein Processing, Post-Translational;
Proteins;
Sumoylation;
Tissue Array Analysis;
Ubiquitin;
Ubiquitination
- From:Soonchunhyang Medical Science
2012;18(2):95-101
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The incidence of colorectal carcinomas continues to rise in Korea due to the westernized life style. However, the precise colorectal carcinogenic mechanisms remain to be elucidated. The protein products of oncogenes and cancer suppressor genes play important roles in the carcinogenesis. The effects of the proteins are influenced by post-translational modifications as phosphorylation, acetylation, methylation, and ubiquitination. The aberrant sumoylation plays some roles in carcinogenesis. However, the expression pattern of small ubiquitin-related modifier (SUMO)-2/3 in the colorectal cancer has not been reported. We assessed the expression of SUMO-2/3 and evaluated the expression pattern in colorectal cancer. METHODS: The SUMO-2/3 expression was tested in one normal colon mucosal cell line and 5 colorectal cancer cell lines by Western blot. We collected 322 cases of colorectal cancer operated from January 2000 to December 2010 at Soonchunhyang University Cheonan Hospital. We fabricated the tissue microarray and the expression of SUMO-2/3 was evaluated by immunohistochemistry. The results were analyzed with clinicopathologic parameters. RESULTS: The SUMO-2/3 was not expressed in the normal colon mucosal cell line. However, it was expressed highly in all the 5 colorectal cancer cell lines as the beta-actin. The SUMO-2/3 was expressed in 68.3% of the colorectal cancers and its expression was correlated with the pathological tumor stage stage (odds ratio, 2.89; 95% confidence interval, 1.10 to 7.55; P=0.031). CONCLUSION: The SUMO-2/3 plays some roles in carcinogenesis and progression of the colorectal cancer.
